Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROMETRIUM.
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone acetate (progestin) and ethinyl estradiol (estrogen) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial lining to reduce implantation. Ethinyl estradiol (in 7-day extended regimen) maintains hormone levels. Ferrous fumarate provides iron supplementation.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
One tablet (containing norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg) orally once daily for 28-day cycle (21 active pills, 7 placebo with ferrous fumarate).
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Norethindrone: Terminal half-life approximately 8–11 hours. Ethinyl estradiol: Terminal half-life approximately 13–27 hours (mean 17 hours). Clinical context: Steady state reached after 5–7 days.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Norethindrone acetate: Urine (39% as metabolites, 1% unchanged); Feces (35% as metabolites). Ethinyl estradiol: Urine (40% as glucuronide conjugates, <1% unchanged); Feces (40% as metabolites). Ferrous fumarate: Iron absorbed and utilized; unabsorbed iron excreted in feces.
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category D/X
Category C
Progestin
Progestin